Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction | Xinxing Li et al. | ResearchPod

Transcript: Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction

Alex: Finding one tumor DNA fragment among a hundred thousand normal ones is mostly a noise problem. This study tackles that noise by making every fragment check itself. That lets a whole-genome blood test spot leftover cancer at a few parts per million.

Sam: Place it for me first. Whose work is this, and what kind of study?

Alex: It's a method paper in EMBO Molecular Medicine from 2024. The authors come from Chinese surgical departments, Yale, and AccuraGen, the company behind the assay. The method is called AccuScan. They pair lab experiments with small retrospective patient cohorts in colorectal, esophageal and melanoma cancer.

Sam: I don't work in cancer diagnostics. Why should I care about one more blood test?

Alex: Because of the decision it feeds. After surgery, doctors want to know about molecular residual disease, meaning cancer cells left behind. That shapes who gets chemotherapy. Current tests either miss many relapses or need custom reagents made for each patient. This one aims for high sensitivity with little blood and no custom reagents. So we'll cover the trick that removes the noise, what it found in patients, and how far to trust it.

Sam: Start with the noise. Why is whole-genome sequencing the hard way to do this?

Alex: The test reads cell-free DNA, the fragments floating in blood plasma. After surgery, the tumor's share can be far below one in ten thousand. One strategy reads a handful of patient-specific mutations very deeply. Another reads the whole genome more shallowly and tracks thousands of tumor mutations at once. Breadth makes up for depth. But ordinary sequencing gets roughly one base in a thousand wrong, so the real signal drowns.

Sam: People already correct errors with molecular barcodes, reading each molecule several times. Why not just do that?

Alex: Barcodes need several separate reads per original molecule. The authors argue that's cost-prohibitive across a whole genome. One earlier whole-genome approach used a machine-learning model to clean reads, and got errors down to about five in a hundred thousand. Duplex methods, which read both DNA strands, go much lower. But they convert few of the input molecules, which hurts sensitivity when DNA is scarce.

Sam: So the gap is error correction that's cheap and doesn't throw away molecules.

Alex: That's it. Here's their idea. Each fragment is unzipped into a single strand and closed into a little circle. Then rolling circle amplification copies it, going round and round. The product is a concatemer, one long strand with the same fragment repeated in tandem. A single sequencing read now holds several copies of one original molecule.

Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction

Xinxing Li, Tao Liu, Antonella Bacchiocchi, Mengxing Li, Wen Cheng, Tobias Wittkop, Fernando L Mendez, Yingyu Wang, Paul Tang, Qianqian Yao, Marcus W Bosenberg, Mario Sznol, Qin Yan, Malek Faham, Li Weng, Ruth Halaban, Hai Jin, Zhiqian Hu

Aug 20, 2024·8:21·user_upload·Original Paper

Molecular Residual Disease (MRD)Circulating tumor DNA (ctDNA)Whole Genome Sequencing (WGS)AccuScanMinimal Residual Disease (MRD)Tumor-informed approach

Listen

8 min

Summary

Research Overview

Detecting molecular residual disease (MRD) after surgical removal of a tumor or during treatment is essential for assessing recurrence risk and guiding therapy. Circulating tumor DNA (ctDNA) is a promising biomarker for this purpose, but conventional whole genome sequencing (WGS) is often limited by high background error rates. This paper introduces AccuScan, a WGS-based technology designed to overcome these limitations by implementing genome-wide error correction at the single-read level.

The AccuScan Approach

AccuScan processes cell-free DNA (cfDNA) by first denaturing and circularizing the fragments, then performing rolling circle amplification. This generates long concatemers containing multiple copies of the original template. During sequencing, these copies are compared; only variants consistent across the tandem copies are retained, while random sequencing or PCR errors are filtered out. By effectively suppressing noise, AccuScan achieves an extremely low error rate of approximately 4.2 x 10^-7, which is roughly 2,000 times lower than standard WGS.

Performance and Clinical Utility

In analytical tests using contrived mixtures of healthy and cancer-derived cfDNA, AccuScan demonstrated high sensitivity at the parts-per-million (PPM) level and consistent specificity. The authors also developed a white blood cell-free (WBC-free) workflow, which leverages post-treatment plasma sequences to filter out germline variants and clonal hematopoiesis, simplifying the logistics compared to traditional tumor-informed approaches that require separate patient-specific assays.

In retrospective clinical cohorts, AccuScan accurately identified patients at high risk for relapse. In colorectal cancer, it showed 90% sensitivity and 100% specificity for predicting recurrence within six weeks of surgery. Similar predictive performance was observed in esophageal cancer. Furthermore, in melanoma patients receiving immunotherapy, AccuScan-measured ctDNA levels provided longitudinal insights into treatment efficacy, effectively correlating with radiographic outcomes and identifying responses even at very low levels of circulating tumor DNA.

Key Terms and Definitions

Molecular Residual Disease (MRD) — The small amount of cancer cells or tumor-derived DNA persisting in a patient following primary treatment.
Concatemer — A long DNA molecule consisting of multiple tandem copies of an original template, created here via rolling circle amplification to facilitate error correction.
Tumor-Informed Approach — A diagnostic strategy that utilizes prior knowledge of patient-specific somatic mutations identified in tumor tissue to specifically search for those markers in blood samples.
Circulating Variant Allele Frequency (cVAF) — The proportion of DNA molecules in a plasma sample that carry a specific tumor-derived mutation.
Clonal Hematopoiesis of Indeterminate Potential (CHIP) — Age-related somatic mutations in blood cells that can cause false-positive results in liquid biopsy assays by mimicking tumor-derived variants.

Abstract

Abstract While whole genome sequencing (WGS) of cell-free DNA (cfDNA) holds enormous promise for detection of molecular residual disease (MRD), its performance is limited by WGS error rate. Here we introduce AccuScan, an efficient cfDNA WGS technology that enables genome-wide error correction at single read-level, achieving an error rate of 4.2 × 10 −7 , which is about two orders of magnitude lower than a read-centric de-noising method. The application of AccuScan to MRD demonstrated analytical sensitivity down to 10 −6 circulating variant allele frequency at 99% sample-level specificity. AccuScan showed 90% landmark sensitivity (within 6 weeks after surgery) and 100% specificity for predicting relapse in colorectal cancer. It also showed 67% sensitivity and 100% specificity in esophageal cancer using samples collected within one week after surgery. When AccuScan was applied to monitor immunotherapy in melanoma patients, the circulating tumor DNA (ctDNA) levels and dynamic profiles were consistent with clinical outcomes. Overall, AccuScan provides a highly accurate WGS solution for MRD detection, empowering ctDNA detection at parts per million range without requiring high sample input or personalized reagents.

Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction: Research Paper Podcast